ced by a 150% improvement in walking distance.
Patients with angina associated with coronary disease given L-arginine (9g/day for 6 months) demonstrated improved acetylcholine-induced coronary vascular relaxation (149% improvement ) with a 70% decrease in anginal episodes. A product for L-arginine supplementation in the form of a medical food has recently been developed (HeartBar); it delivers L-arginine and a number of other antioxidants, vitamins and fiber. These other components have been shown to be of some benefit to patients with cardiovascular disease.Studies clearly demonstrate the potential of L-arginine supplementation to enhance NO-mediated cardiovascular health. The risk associated with-L-arginine therapy appears minimal, except in a very small subset of patients (e.g., active malignancies, severe fection,diabetic retinopathy)
Patients should consult their healthcare providers about using products containing L-arginine for cardiovascular benefits.
< ÀúÀÛ±ÇÀÚ © ¾à±¹½Å¹® ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö > |